A critical breakthrough in CF therapeutic development was the discovery that the addition of either elexacaftor or VX-659 to TEZ/IVA increases mature CFTR and improves chloride ion transport when compared to either drug alone or dual combinations in epithelial cells from MF/F508del and F508del/F508del donors [86,87]. This evidence concerns the gene CFTR and cystic fibrosis.